Patents by Inventor Casey Cameron McComas

Casey Cameron McComas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 4-AMINOPHENYL-THIAZOLE DERIVATIVES AND METHODS OF USE THEREOF
    Publication number: 20250276952
    Abstract: The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable prodrugs, solvates, or salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for the treatment of disorders such as a cancer or a neurodegenerative disease.
    Type: Application
    Filed: April 25, 2023
    Publication date: September 4, 2025
    Inventors: Matthew Alan BELMONTE, William D. BRADLEY, Jean-Marc LAPIERRE, Casey Cameron MCCOMAS, John Paul SECRIST, Joseph VACCA
  • METHODS OF USING A (THIAZOLYL)BENZENESULFONAMIDE DERIVATIVE
    Publication number: 20250268869
    Abstract: This application is directed to inhibitors of represented by the following structural formula, and methods for their use in modulating MCT in a disease or disorder, such as cancer or neurodegenerative diseases.
    Type: Application
    Filed: April 25, 2023
    Publication date: August 28, 2025
    Inventors: Matthew Alan BELMONTE, William D. BRADLEY, Jean-Marc LAPIERRE, Casey Cameron MCCOMAS, John Paul SECRIST, Joseph VACCA
  • METHODS OF USING A (THIAZOLYL)BENZENESULFONAMIDE DERIVATIVE
    Publication number: 20250186404
    Abstract: This application is directed to modulators of MCT represented by the following structural formula (I) and methods for their use, such as to treat cancer or neurodegenerative diseases.
    Type: Application
    Filed: April 25, 2023
    Publication date: June 12, 2025
    Inventors: Matthew Alan BELMONTE, William D. BRADLEY, Casey Cameron MCCOMAS, John Paul SECRIST, Joseph VACCA
  • MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE
    Publication number: 20250136606
    Abstract: The present disclosure relates to pharmaceutical compounds of the Formula (I), (Ia), (Ib), or (Ic) or a pharmaceutically acceptable salt or composition thereof. Also provided are methods of use of TRPML modulators for treating disorders, the modulators including compounds of the Formula (I), (Ia), (Ib), or (Ic). Such methods of use include treatment of ciliopathies.
    Type: Application
    Filed: September 29, 2022
    Publication date: May 1, 2025
    Applicant: Caraway Therapeutics, Inc.
    Inventors: Rajesh R. IYENGAR, Thomas Wai-Ho Lee, Casey Cameron McComas, Darby R. Schmidt, John J. Graziotto
  • RAD51 INHIBITORS
    Publication number: 20250136591
    Abstract: This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.
    Type: Application
    Filed: August 29, 2024
    Publication date: May 1, 2025
    Inventors: Alfredo C. CASTRO, Casey Cameron MCCOMAS, Joseph VACCA, Tyler MACLAY
  • METHODS OF USING RAD51 INHIBITORS FOR TREATMENT OF PANCREATIC CANCER
    Publication number: 20250082614
    Abstract: This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for their use, such as to treat pancreatic cancer.
    Type: Application
    Filed: July 9, 2024
    Publication date: March 13, 2025
    Inventors: Alfredo C. CASTRO, Melinda DAY, Tyler MACLAY, Casey Cameron MCCOMAS, Kevin MILLS, Joseph VACCA
  • MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE
    Publication number: 20240398812
    Abstract: The present disclosure relates to pharmaceutical compounds of the Formulas I, Ia, Ib, or Ic or a pharmaceutically acceptable salt or composition thereof. Also provided are methods of use of TRPML modulators for treating disorders, the modulators including compounds of the Formulas I, Ia, Ib, or Ic. Such methods of use include treatment of ciliopathies.
    Type: Application
    Filed: September 29, 2022
    Publication date: December 5, 2024
    Applicant: Caraway Therapeutics, Inc.
    Inventors: Rajesh R. IYENGAR, Thomas Wai-Ho Lee, Casey Cameron McComas, Darby R. Schmidt, John J. Graziotto
  • RAD51 INHIBITORS
    Publication number: 20240360120
    Abstract: This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.
    Type: Application
    Filed: January 30, 2024
    Publication date: October 31, 2024
    Inventors: Jean-Marc LAPIERRE, Casey Cameron MCCOMAS, Joseph VACCA
  • Methods of using RAD51 inhibitors for treatment of pancreatic cancer
    Patent number: 12064419
    Abstract: This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for their use, such as to treat pancreatic cancer.
    Type: Grant
    Filed: June 22, 2020
    Date of Patent: August 20, 2024
    Assignee: Cyteir Therapeutics, Inc.
    Inventors: Alfredo C. Castro, Melinda Day, Tyler Maclay, Casey Cameron McComas, Kevin Mills, Joseph Vacca
  • RAD51 inhibitors
    Patent number: 11932636
    Abstract: This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.
    Type: Grant
    Filed: December 16, 2021
    Date of Patent: March 19, 2024
    Assignee: Cyteir Therapeutics, Inc.
    Inventors: Jean-Marc Lapierre, Casey Cameron McComas, Joseph Vacca
  • Combinations of RAD51 and PARP inhibitors
    Patent number: 11607404
    Abstract: This application is directed to inhibitors of RAD51 represented by the following structural formula: in combination with a PARP inhibitor, and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.
    Type: Grant
    Filed: March 25, 2020
    Date of Patent: March 21, 2023
    Assignee: Cyteir Therapeutics, Inc.
    Inventors: Alfredo C. Castro, Melinda Day, Tyler Maclay, Casey Cameron McComas, Kevin Mills, Joseph Vacca
  • RAD51 INHIBITORS
    Publication number: 20220259198
    Abstract: This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.
    Type: Application
    Filed: December 16, 2021
    Publication date: August 18, 2022
    Inventors: Jean-Marc LAPIERRE, Casey Cameron MCCOMAS, Joseph VACCA
  • RAD51 inhibitors
    Patent number: 11291655
    Abstract: This application is directed to inhibitors of RAD51, and methods for their use, such as to treat or prevent conditions involving mitochondrial defects.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: April 5, 2022
    Assignee: Cyteir Therapeutics, Inc.
    Inventors: Alfredo C. Castro, Casey Cameron McComas, Joseph Vacca
  • RAD51 INHIBITORS
    Publication number: 20220056022
    Abstract: This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.
    Type: Application
    Filed: June 30, 2021
    Publication date: February 24, 2022
    Inventors: Alfredo C. CASTRO, Casey Cameron MCCOMAS, Joseph VACCA, Tyler MACLAY
  • RAD51 inhibitors
    Patent number: 11247988
    Abstract: This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.
    Type: Grant
    Filed: March 12, 2020
    Date of Patent: February 15, 2022
    Assignee: Cyteir Therapeutics, Inc.
    Inventors: Jean-Marc Lapierre, Casey Cameron McComas, Joseph Vacca
  • RAD51 inhibitors
    Patent number: 11084812
    Abstract: This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.
    Type: Grant
    Filed: January 6, 2020
    Date of Patent: August 10, 2021
    Assignee: Cyteir Therapeutics, Inc.
    Inventors: Alfredo C. Castro, Casey Cameron McComas, Joseph Vacca, Tyler Maclay
  • METHODS OF USING RAD51 INHIBITORS FOR TREATMENT OF PANCREATIC CANCER
    Publication number: 20200397760
    Abstract: This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for their use, such as to treat pancreatic cancer.
    Type: Application
    Filed: June 22, 2020
    Publication date: December 24, 2020
    Inventors: Alfredo C. CASTRO, Melinda DAY, Tyler MACLAY, Casey Cameron MCCOMAS, Kevin MILLS, Joseph VACCA
  • COMBINATIONS OF RAD51 AND PARP INHIBITORS
    Publication number: 20200306229
    Abstract: This application is directed to inhibitors of RAD51 represented by the following structural formula: in combination with a PARP inhibitor, and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.
    Type: Application
    Filed: March 25, 2020
    Publication date: October 1, 2020
    Inventors: Alfredo C. CASTRO, Melinda DAY, Tyler MACLAY, Casey Cameron MCCOMAS, Kevin MILLS, Joseph VACCA
  • RAD51 INHIBITORS
    Publication number: 20200291014
    Abstract: This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.
    Type: Application
    Filed: March 12, 2020
    Publication date: September 17, 2020
    Inventors: Jean-Marc LAPIERRE, Casey Cameron MCCOMAS, Joseph VACCA
  • RAD51 INHIBITORS
    Publication number: 20200216437
    Abstract: This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.
    Type: Application
    Filed: January 6, 2020
    Publication date: July 9, 2020
    Inventors: Alfredo C. CASTRO, Casey Cameron MCCOMAS, Joseph VACCA, Tyler MACLAY